Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Fasenra
Pharma
In battle with GSK's Nucala, AZ's Fasenra wins FDA nod for EGPA
The FDA has signed off on AstraZeneca's Fasenra to treat eosinophilic granulomatosis with polyangiitis, a rare, immune-mediated vascular disorder.
Kevin Dunleavy
Sep 18, 2024 11:46am
AstraZeneca steps up to show Fasenra helping patients step out
Mar 25, 2024 9:56am
AZ's Fasenra shows comparable efficacy in trial vs. GSK's Nucala
Sep 12, 2023 9:01am
AstraZeneca unifies patient-doc messaging for asthma blockbuster
May 17, 2023 7:40am
COPD trial data coming soon for Sanofi, Regneron’s Dupixent
Mar 20, 2023 8:34am
Pharma sings for its supper at the Grammys
Feb 8, 2023 12:33pm
